2-[4-[3-[(ethenylsulfonylamino)methyl]pyrrolidin-1-yl]sulfonylphenyl]-N-(1-propan-2-ylpiperidin-4-yl)acetamide
C23H36N4O5S2 — CID 146211783
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[4-[3-[(ethenylsulfonylamino)methyl]pyrrolidin-1-yl]sulfonylphenyl]-N-(1-propan-2-ylpiperidin-4-yl)acetamide
2-[4-[3-[(ethenylsulfonylamino)methyl]pyrrolidin-1-yl]sulfonylphenyl]-N-(1-propan-2-ylpiperidin-4-yl)acetamide (PubChem CID 146211783) has the molecular formula C23H36N4O5S2 and a molecular weight of 512.70 g/mol. Its IUPAC name is 2-[4-[3-[(ethenylsulfonylamino)methyl]pyrrolidin-1-yl]sulfonylphenyl]-N-(1-propan-2-ylpiperidin-4-yl)acetamide.
Molecular Properties
| Compound Name | 2-[4-[3-[(ethenylsulfonylamino)methyl]pyrrolidin-1-yl]sulfonylphenyl]-N-(1-propan-2-ylpiperidin-4-yl)acetamide |
|---|---|
| PubChem CID | 146211783 |
| Molecular Formula | C23H36N4O5S2 |
| Molecular Weight | 512.70 g/mol |
| Exact Mass | 512.21 |
| IUPAC Name | 2-[4-[3-[(ethenylsulfonylamino)methyl]pyrrolidin-1-yl]sulfonylphenyl]-N-(1-propan-2-ylpiperidin-4-yl)acetamide |
| SMILES | C=CS(=O)(=O)NCC1CCN(S(=O)(=O)c2ccc(CC(=O)NC3CCN(C(C)C)CC3)cc2)C1 |
| InChI | InChI=1S/C23H36N4O5S2/c1-4-33(29,30)24-16-20-9-14-27(17-20)34(31,32)22-7-5-19(6-8-22)15-23(28)25-21-10-12-26(13-11-21)18(2)3/h4-8,18,20-21,24H,1,9-17H2,2-3H3,(H,25,28) |
| InChIKey | IWQZBYKNKMPMOT-UHFFFAOYSA-N |
| XLogP | 1.29 |
| TPSA | 115.89 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 512.70 |
| LogP ≤ 5 | 1.29 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 146211783 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.